News

Milk production hormone prolactin linked to active NMOSD, study finds

Blood levels of prolactin, a hormone mostly known for its role in milk production, are significantly elevated in people with neuromyelitis optica spectrum disorder (NMOSD) as compared with healthy adults, a study found. Among NMOSD patients, these high prolactin levels were significantly associated with active disease, sensory-related symptoms, and…

Ultomiris now approved in Canada for AQP4-positive NMOSD adults

Ultomiris (ravulizumab) is now approved in Canada to treat adults with neuromyelitis optica spectrum disorder (NMOSD) who are positive for antibodies against aquaporin-4 (AQP4). According to a press release from Alexion Canada, which will market Ultomiris in the country, it’s the “first and only” long-acting therapy…

Uplizna effective in patients with or without genetic variant: Data

Uplizna (inebilizumab) prevented disease attacks for people with neuromyelitis optica spectrum disorder (NMOSD) regardless of whether they had a genetic variant in the FCGR3A gene that’s associated with reduced efficacy of rituximab, a therapy commonly used off-label for NMOSD. That’s according to additional data analyses from the Phase…

Soliris now approved in China to treat adults with NMOSD

Soliris (eculizumab) has been approved in China to treat adults with neuromyelitis optica spectrum disorder, known as NMO or NMOSD, who test positive for antibodies against the aquaporin-4 (AQP4) protein. The therapy — which works to reduce the risk of relapse and ease inflammation among patients — was approved…

ECTRIMS 2023: NMOSD disability progresses faster than in MOGAD

People with neuromyelitis optica spectrum disorder (NMOSD) experience faster disability progression with fewer attacks than those with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), a related condition, according to a long-term analysis of German registry data. Notably, in all patients, experiencing inflammation in the optic nerve, which transmits signals between…

ECTRIMS 2023: Early, nonspecific symptoms may precede 1st attack

Nearly 1 in 5 people with neuromyelitis optica spectrum disorder (NMOSD) experience early neurological symptoms prior to their first established NMOSD attack, new research suggests. These symptoms could represent an NMOSD prodrome, a disease stage where nonspecific symptoms emerge before the classic manifestations of the disease. A better…

Involuntary function problems linked to worse life quality

Problems in the autonomic nervous system (ANS), which regulates involuntary bodily processes such as heart rate, blood pressure, and digestion, are very frequent among people with neuromyelitis optica spectrum disorder (NMOSD), a study has shown. All 80 NMOSD patients in the study experienced ANS-related symptoms, and a greater burden…

Symptoms like a stroke may be seen in NMOSD patients over 50

The clinical symptoms of neuromyelitis optica spectrum disorder (NMOSD) in people in their 50s or older may look like those of a stroke — which can delay proper diagnosis and treatment of the the progressive autoimmune disorder, according to a case report and systematic literature review. That’s what happened…

Genetic data suggest causal link between COVID-19, NMOSD

People with a genetic makeup that causes them to be more susceptible to COVID-19 are nearly five times as likely to develop neuromyelitis optica spectrum disorder (NMOSD) associated with antibodies against aquaporin-4 (AQP4), a study finds. Evidence for a cause and effect, or causal, link between COVID-19 and NMOSD…